



For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only.

Meropenem
AMERO 500 / AMERO 1G
500 mg / 1g Powder For Injection
Antibacterial



Composition of the product:

AMERO 1G

Each vial contains :
Meropenem Trihydrate USP
equivalent to Anhydrous Meropenem 1000mg
Sodium Carbonate USP
equivalent to Sodium 90.2 mg
(as buffer)

AMERO 500

Each vial contains :
Meropenem Trihydrate USP
equivalent to Anhydrous Meropenem 500 mg
Sodium Carbonate USP
equivalent to Sodium 45.1 mg
(as buffer)

Pharmaceutical form:

Powder for solution for injection or infusion.
A white to off white crystalline powder.

Clinical Particulars:

Therapeutic Indications: Meropenem is indicated for the treatment of the following infections in adults and children over 3 months of age:

- Pneumonia, including community acquired pneumonia and nosocomial pneumonia
- Broncho pulmonary infections in cystic fibrosis
- Complicated urinary tract infections
- Complicated intra-abdominal infections
- Intra- and post-partum infections
- Complicated skin and soft tissue infections
- Acute bacterial meningitis

Meropenem may be used in the management of neutropenic patients with fever that is suspected to be due to bacterial infection. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Posology and method of administration

Adults:

The tables below provide general recommendations for dosing.

The dose of Meropenem administered and the duration of treatment should take into account the type of infection to be treated, including its severity, and the clinical response.

A dose of 2 g three times daily in adults and adolescents and a dose of up to 40 mg/kg three times daily in children may be particularly appropriate when treating some types of infections, such as nosocomial infections due to *Pseudomonas aeruginosa* or *Acinetobacter* spp.

Additional considerations for dosing are needed when treating patients with renal insufficiency (see further below).

Adults and adolescents

Infection	Dose to be administered every 8 hours
Pneumonia including community-acquired pneumonia and nosocomial pneumonia	500 mg or 1 g
Broncho-pulmonary infections in cystic fibrosis	2 g
Complicated urinary tract infections	500 mg or 1 g
Complicated intra-abdominal infections	500 mg or 1 g
Intra- and post-partum infections	500 mg or 1 g
Complicated skin and soft tissue infections	500 mg or 1 g
Acute bacterial meningitis	2 g
Management of febrile neutropenic patients	1 g

Meropenem is usually given by intravenous infusion over approximately 15 to 30 minutes. Alternatively, doses up to 1 g can be given as an intravenous bolus injection over approximately 5 minutes. There are limited safety data available to support the administration of a 2 g dose in adults as an intravenous bolus injection.

Renal impairment: The dose for adults and adolescents should be adjusted when creatinine clearance is less than 51 ml/min, as shown below. There are limited data to support the application of these dose adjustments for a unit dose of 2 g.

Creatinine clearance (ml/min)	Dose (based on "unit" dose range of 500 mg or 1 g or 2 g, see table above)	Frequency
26 - 50	one unit dose	every 12 hours
10 - 25	half of one unit dose	every 12 hours
< 10	half of one unit dose	every 24 hours

Meropenem is cleared by haemodialysis and haemofiltration. The required dose should be administered after completion of the haemodialysis cycle.

There are no established dose recommendations for patients receiving peritoneal dialysis.

Hepatic impairment

No dose adjustment is necessary in patients with hepatic impairment.

Dose in elderly patients

No dose adjustment is required for the elderly with normal renal function or creatinine clearance values above 50 ml/min.

Paediatric population

Children under 3 months of age

The safety and efficacy of Meropenem in children under 3 months of age have not been established and the optimal dose regimen has not been identified. However, limited pharmacokinetic data suggest that 20 mg/kg every 8 hours may be an appropriate regimen.

Children from 3 months to 11 years of age and up to 50 kg body weight

The recommended dose regimens are shown in the table below:

Infection	Dose to be administered every 8 hours
Pneumonia including community-acquired pneumonia and nosocomial pneumonia	10 or 20 mg/kg
Broncho-pulmonary infections in cystic fibrosis	40 mg/kg
Complicated urinary tract infections	10 or 20 mg/kg
Complicated intra-abdominal infections	10 or 20 mg/kg
Complicated skin and soft tissue infections	10 or 20 mg/kg
Acute bacterial meningitis	40 mg/kg
Management of febrile neutropenic patients	20 mg/kg

Children over 50 kg body weight

The adult dose should be administered.

There is no experience in children with renal impairment.

Meropenem is usually given by intravenous infusion over approximately 15 to 30 minutes. Alternatively, meropenem doses of up to 20 mg/kg may be given as an intravenous bolus over approximately 5 minutes. There are limited safety data available to support the administration of a 40 mg/kg dose in children as an intravenous bolus injection.

Contraindications

Hypersensitivity to the active substance or to any of the excipients.

Hypersensitivity to any other carbapenem antibacterial agent.

Severe hypersensitivity (e.g. anaphylactic reaction, severe skin reaction) to any other type of beta-lactam antibacterial agent (e.g. penicillins or cephalosporins).

Warnings and Precautions:

The selection of meropenem to treat an individual patient should take into account the appropriateness of using a carbapenem antibacterial agent based on factors such as severity of the infection, the prevalence of resistance to other suitable antibacterial agents and the risk of selecting for carbapenem-resistant bacteria.

As with all beta-lactam antibiotics, serious and occasionally fatal hypersensitivity reactions have been reported.

Patients who have a history of hypersensitivity to carbapenems, penicillins or other beta-lactam antibiotics may also be hypersensitive to Meropenem. Before initiating therapy with Meropenem, careful enquiry should be made concerning previous hypersensitivity reactions to beta-lactam antibiotics.

If severe allergic reaction occurs, the medicinal product should be discontinued and appropriate measures taken.

Antibiotic-associated colitis and pseudomembranous colitis have been reported with nearly all antibacterial agents, including meropenem, and may range in severity from mild to life threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of meropenem. Discontinuation of therapy with meropenem and the administration of specific treatment for *Clostridium difficile* should be considered.

Medicinal products that inhibit peristalsis should not be given.

Seizures have infrequently been reported during treatment with carbapenems, including meropenem.

Hepatic function should be closely monitored during treatment with meropenem due to the risk of hepatic toxicity (hepatic dysfunction with cholestasis and cytolytic).

Use in patients with liver disease: patients with pre-existing liver disorders should have liver function monitored during treatment with meropenem. There is no dose adjustment necessary.

A positive direct or indirect Coombs test may develop during treatment with meropenem.

The concomitant use of meropenem and valproic acid/sodium valproate is not recommended.

Meropenem contains sodium.

Meropenem 500 mg Powder for Solution for Injection or Infusion contains approximately 2.0 mEq of

sodium per vial which should be taken into consideration by patients on a controlled sodium diet.

Drug and Laboratory Interactions

No specific medicinal product interaction studies other than probenecid have been conducted. Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem with the effect of increasing the elimination half-life and plasma concentration of meropenem. Caution is required if probenecid is co-administered with meropenem.

The potential effect of meropenem on the protein binding of other medicinal products or metabolism has not been studied. However, the protein binding is so low that no interactions with other compounds would be expected on the basis of this mechanism.

Decreases in blood levels of valproic acid have been reported when it is co-administered with carbapenem agents resulting in 60-100% decrease in valproic acid levels in about two days. Due to the rapid onset and the extent of the decrease, co-administration of valproic acid with carbapenem agents is not considered to be manageable and therefore should be avoided.

Oral anti-coagulants

Simultaneous administration of antibiotics with warfarin may augment its anti-coagulant effects. There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents. The risk may vary with the underlying infection, age and general status of the patient so that the contribution of the antibiotic to the increase in INR (international normalised ratio) is difficult to assess. It is recommended that the INR should be monitored frequently during and shortly after co-administration of antibiotics with an oral anti-coagulant agent.

Pregnancy and Lactation

Pregnancy

There are no or limited amount of data from the use of meropenem in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. As a precautionary measure, it is preferable to avoid the use of meropenem during pregnancy.

Lactation

It is unknown whether meropenem is excreted in human milk. Meropenem is detectable at very low concentrations in animal breast milk. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from meropenem therapy taking into account the benefit of therapy for the woman.

Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed.

Undesirable effects

Adverse events are listed below by system organ class and frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100 and <1/10), uncommon (≥1/1000 and <1/100), rare (≥1/10,000 and <1/1000) and very rare (<1/10,000) including isolated reports.

System Organ Class	Frequency	Event
Infections and infestations	Uncommon	Oral and vaginal candidiasis
Blood and lymphatic system disorders	Common	Thrombocythaemia
	Uncommon	Eosinophilia, thrombocytopenia, leucopenia, neutropenia
	Not known	Agranulocytosis, haemolytic anaemia
Immune system disorders	Not known	Angioedema, anaphylaxis
Nervous system disorders	Common	Headache
	Uncommon	Paraesthesiae
	Rare	Convulsions
Gastrointestinal disorders	Common	Diarrhoea, vomiting, nausea, abdominal pain
	Not known	Antibiotic-associated colitis
Hepatobiliary disorders	Common	Transaminases increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased
	Uncommon	Blood bilirubin increased
Skin and subcutaneous tissue disorders	Common	Rash, pruritis
	Uncommon	Urticaria
	Not known	Toxic epidermal necrolysis, Stevens Johnson syndrome, erythema multiforme
Renal and urinary disorders	Uncommon	Blood creatinine increased, blood urea increased
General disorders and administration site	conditions	Common Inflammation, pain
	Uncommon	Thrombophlebitis
	Not known	Pain at the injection site

PH

Overdose

Relative overdose may be possible in patients with renal impairment if the dose is not adjusted as described. Limited post-marketing experience indicates that if adverse reactions occur following overdose, they are consistent with the adverse reaction profile described earlier, are generally mild in severity and resolve on withdrawal or dose reduction. Symptomatic treatments should be considered.

In individuals with normal renal function, rapid renal elimination will occur, Haemodialysis will remove meropenem and its metabolite.

Pharmacological Properties

Pharmacodynamic properties

Pharmacotherapeutic group: antibacterials for systemic use, carbapenems, ATC code: J01DH02

Mode of action

Meropenem exerts its bactericidal activity by inhibiting bacterial cell wall synthesis in Gram-positive and Gram-negative bacteria through binding to penicillin-binding proteins (PBPs).

Pharmacokinetic/Pharmacodynamic (PK/PD) relationship

Similar to other beta-lactam antibacterial agents, the time that meropenem concentrations exceed the MIC (T>MIC) has been shown to best correlate with efficacy. In preclinical models meropenem demonstrated activity when plasma concentrations exceeded the MIC of the infecting organisms for approximately 40% of the dosing interval. This target has not been established clinically.

Mechanism of resistance

Bacterial resistance to meropenem may result from: (1) decreased permeability of the outer membrane of Gram-negative bacteria (due to diminished production of porins) (2) reduced affinity of the target PBPs (3) increased expression of efflux pump components, and (4) production of beta-lactamases that can hydrolyse carbapenems.

Localised clusters of infections due to carbapenem-resistant bacteria have been reported in the European Union.

There is no target-based cross-resistance between meropenem and agents of the quinolone, aminoglycoside, macrolide and tetracycline classes. However, bacteria may exhibit resistance to more than one class of antibacterial agents when the mechanism involved includes impermeability and/or an efflux pump(s).

Breakpoints

European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints for MIC testing are presented below.

EUCAST clinical MIC breakpoints for meropenem (2009-06-05, v 3.1)

Organism	Susceptible (S) (mg/l)	Resistant (R) (mg/l)
Enterobacteriaceae	≤2	>8
Pseudomonas	≤2	>8
Actinobacter	≤2	>8
Streptococcus groups A, B, C, G	≤2	>2
Streptococcus pneumoniae ¹	≤2	>2
Other streptococci	2	2
Enterococcus	--	--
Staphylococcus ²	note ³	note ³
Haemophilus influenzae ¹ and Moraxella catarrhalis	≤2	>2
Neisseria meningitidis ^{1,4}	≤0.25	>0.25
Gram-positive anaerobes	≤2	>8
Gram-negative anaerobes	≤2	>8
Non-species related breakpoints ⁵	≤2	>8

1 Meropenem breakpoints for Streptococcus pneumoniae and Haemophilus influenzae in meningitis are 0.25/1 mg/L.

2 Strains with MIC values above the S/I breakpoint are rare or not yet reported. The identification and antimicrobial susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current breakpoint (in *italics*) they should be reported as resistant.

3 Susceptibility of staphylococci to meropenem is inferred from the methicillin susceptibility.

4 Meropenem breakpoints in Neisseria meningitidis relates to meningitis only.

5 Non-species related breakpoints have been determined mainly from PK/PD data and are independent of the MIC distributions of specific species. They are for use for species not mentioned in the table and footnotes.

-- = Susceptibility testing not recommended as the species is a poor target for therapy with the medicinal product.

The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.

The following table of pathogens listed is derived from clinical experience and therapeutic guidelines.

Commonly susceptible species

Gram-positive aerobes

*Enterococcus faecalis*²

Staphylococcus aureus (methicillin-susceptible)²

Staphylococcus species (methicillin-susceptible) including *Staphylococcus epidermis*

Streptococcus agalactiae (Group B)

Streptococcus milleri group (S. anginosus, S. constellatus, and S. intermedius)

Streptococcus pneumoniae

Streptococcus pyogenes (Group A)

Gram-negative aerobes

Citrobacter freundii

Citrobacter koseri

Enterobacter aerogenes

Enterobacter cloacae

Escherichia coli

Haemophilus influenzae

Klebsiella oxytoca

Klebsiella pneumoniae

Morganella morganii

Neisseria meningitidis

Proteus mirabilis

Proteus vulgaris

Serratia marcescens

Gram-positive anaerobes

Clostridium perfringens

Peptoniphilus asaccharolyticus

Peptostreptococcus species (including *P. micros*, *P. anaerobius*, *P. magnus*)

Gram-negative anaerobes

Bacteroides spp.

Bacteroides fragilis group

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Prevotella spp.

Meropenem is cleared by haemodialysis with clearance during haemodialysis being approximately 4 times higher than in anuric patients.

Pediatrics

The pharmacokinetics in infants and children with infection at doses of 10, 20 and 40 mg/kg showed C_{max} values approximating to those in adults following 500, 1000 and 2000 mg doses respectively. Comparison showed consistent pharmacokinetics between the doses and half-lives similar to those observed in adults in all but the youngest subjects (<6 months 11/2 to 1.6 hours). The mean meropenem clearance values were 5.8 ml/min/kg (6-12 years), 6.2 ml/min/kg (2-5 years), 5.3 ml/min/kg (6-23 months) and 4.3 ml/min/kg (2-5 months). Approximately 60% of the dose is excreted in urine over 12 hours as meropenem with a further 12% as metabolite. Meropenem concentrations in the CSF of children with meningitis are approximately 20% of concurrent plasma levels although there is significant inter-individual variability.

The pharmacokinetics of meropenem in neonates requiring anti-infective treatment showed greater clearance in neonates with higher chronological or gestational age with an overall average half-life of 2.9 hours. Monte Carlo simulation based on a population PK model showed that a dose regimen of 20 mg/kg 8 hourly achieved 60% T>MIC for P.aeruginosa in 95% of pre-term and 91% of full-term neonates.

Elderly

No dose adjustment is required in elderly patients, except in cases of moderate to severe renal impairment.

Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned.

Caution: Foods, Drugs, Devices & Cosmetics Act prohibits dispensing without prescription.

For suspected adverse drug reactions, report to FDA: www.fda.gov.ph

Shelf life: 24 months

Storage: Store at temperatures not exceeding 30°C. Protect from light.

Availability:

1 vial x 500 mg Powder for Injection

1 vial x 1 g Powder for Injection

Instructions for Use/Handling

Administer by IV injection or infusion.

IV Injection

Reconstitution and Dilution

Reconstitute single-use vials containing 0.5g/1 g with 10 or 20 mL, respectively, of sterile water for injection to provide a solution containing approximately 50 mg/mL. The vial should be shaken until dissolution occurs and then allowed to stand until the solution is clear.

Rate of Administration

The appropriate dose of reconstituted solution should be injected over a period of 3–5 minutes.

IV Infusion

Reconstitution and Dilution

Reconstitute infusion vials containing 0.5 g/1 g with a compatible IV solution 10 or 20 mL (e.g., 0.9% sodium chloride, 5% dextrose) to provide solutions containing approximately 50 mg/mL. Alternatively, reconstitute vials containing 0.5 g/1 g with 10 or 20 mL, respectively, of sterile water for injection and then further dilute in a compatible IV.

Rate of Administration

Infuse IV over 15-30 minutes.

Shake constituted solution before use.

It is recommended to use freshly prepared solutions of Amero for IV, injection and infusion.

Reconstituted product, constituted as described above, maintains satisfactory potency at room temperature (up to 25°C) or under refrigeration (4°C) as shown in the following table:

Diluent	Hours stable
Sterile water for injection	3 hours at 15-25°C 16 hours at 2-8°C
0.9% Sodium Chloride	6 hours at 15-25°C 30 hours at 2-8°C
5 % Dextrose Injection	2 hours at 15-25°C 6 hours at 2-8°C
10% Dextrose Injection	2 hours at 15-25°C 3 hours at 2-8°C
5% Dextrose and 0.9% Sodium Chloride Injection	2 hours at 15-25°C 3 hours at 2-8°C
Ringer Lactate Injection	6 hours at 15-25°C 16 hours at 2-8°C

Date of First Authorization: 14 March 2022

Date of Revision of Package Insert: 23 May 2023

Caution: Foods, Drugs, Devices & Cosmetics Act prohibits dispensing without prescription

For suspected adverse drug reactions, report to FDA: www.fda.gov.ph or pv@biocarelifesciences.com

Imported and Distributed by:

biocare

LIFESCIENCES INC

4th Floor, 393 Goodwill Bldg., Senator Gil Puyat Ave.,

Brgy. Bel-Air, Makati, Metro Manila

Manufactured by:

Brooks Steriscience

Limited

Unit II, Village Mangley, Nareswar Road, Off NH-8,

Taluka-Karjan, Dist. V Adodara Gujarat -391210, India